{
  "channel": "\ud83c\udf52-select-news",
  "messages": [
    {
      "id": "1139240765260836936-1451182947800711178",
      "content": "07:02  \u2191  ATHA  < $7  ~  :flag_us:  |  Float: 3.8 M  |  IO: 43.72%  |  MC: 16.3 M\n11 seconds ago  PR  Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million - Link,",
      "timestamp": "2025-12-18T12:02:56.431Z",
      "author": "NuntioBot"
    }
  ],
  "sent_at": "2025-12-18T12:02:57.197Z"
}